United Therapeutics Buys Thymmune For Up To $300M
Biotechnology firm United Therapeutics Corp. on Thursday revealed that it has agreed to buy a preclinical-stage biotech company focused on thymic cell therapies in a deal worth up to $300 million....To view the full article, register now.
Already a subscriber? Click here to view full article